Monthly Archives: May 2025

AB Science announces the successful completion of a EUR 1.8 million private placement

20/05/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.8 million subscribed by a limited number of investors

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041

19/05/2025 – AB Science today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 infection causing COVID-19

AB Science reports a new publication in the scientific journal PLOS One

15/05/2025 – AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib

CNews – Interview of Alain Moussy

Alain Moussy is interviewed by Sophie de Menthon in the show “Patrons en Question”.

Annual financial results as of 31 December, 2024

12/05/2025 – AB Science reports its revenues for the year 2024 and provides an update on its activities

AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting

05/05/2025 – AB Science announced that new analyses from its phase 3 trial in ALS and preclinical animal model data have been accepted for presentation at the ENCALS annual meeting (June 3-6, 2025, Turin, Italy)

AB Science will publish its 2024 annual financial report on May 9, 2025

01/05/2025 – AB Science today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time to complete their audit work